Entera Bio Ltd. (ENTX) SEC filings

ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/30

$3.11−0.11 (-3.42%)

Close on Nov 13, 2026Market cap $538.47MP/E –Yield –

SEC filings

40 of Entera Bio's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 6, 2026	SEC EDGAR
Current report	8-K	Nov 6, 2026	Nov 6, 2026	SEC EDGAR
Current report	8-K	Oct 27, 2026	Oct 27, 2026	SEC EDGAR
Proxy statement	DEF 14A	Oct 14, 2026	Oct 14, 2026	SEC EDGAR
Current report	8-K	Oct 6, 2026	Oct 6, 2026	SEC EDGAR
Current report	8-K	Aug 18, 2026	Aug 18, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 7, 2026	SEC EDGAR
Current report	8-K	Aug 7, 2026	Aug 7, 2026	SEC EDGAR
Current report	8-K	Jul 26, 2026	Jul 28, 2026	SEC EDGAR
Current report	8-K	Jul 14, 2026	Jul 16, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 3, 2026	Jun 3, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 8, 2026	SEC EDGAR
Current report	8-K	May 8, 2026	May 8, 2026	SEC EDGAR
Current report	8-K	Apr 1, 2026	Apr 3, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 27, 2026	SEC EDGAR
Current report	8-K	Mar 27, 2026	Mar 27, 2026	SEC EDGAR
Current report	8-K	Mar 4, 2026	Mar 4, 2026	SEC EDGAR
Current report	8-K	Feb 4, 2026	Feb 9, 2026	SEC EDGAR
Current report	8-K	Jan 29, 2026	Feb 4, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 14, 2025	SEC EDGAR
Current report	8-K	Nov 14, 2025	Nov 14, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 8, 2025	SEC EDGAR
Current report	8-K	Aug 8, 2025	Aug 8, 2025	SEC EDGAR
Current report	8-K	Jul 28, 2025	Jul 28, 2025	SEC EDGAR
Current report	8-K	Jul 16, 2025	Jul 18, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 5, 2025	Jun 5, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 9, 2025	SEC EDGAR
Current report	8-K	May 9, 2025	May 9, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 28, 2025	SEC EDGAR
Current report	8-K	Mar 28, 2025	Mar 28, 2025	SEC EDGAR
Current report	8-K	Mar 16, 2025	Mar 17, 2025	SEC EDGAR
Current report	8-K	Jan 10, 2025	Jan 10, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 8, 2024	SEC EDGAR
Current report	8-K	Nov 8, 2024	Nov 8, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 9, 2024	SEC EDGAR
Current report	8-K	Aug 9, 2024	Aug 9, 2024	SEC EDGAR
Current report	8-K	Jul 31, 2024	Aug 2, 2024	SEC EDGAR
Proxy statement	DEF 14A	Jun 20, 2024	Jun 20, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 10, 2024	SEC EDGAR
Current report	8-K	May 10, 2024	May 10, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Entera Bio's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ENTX.

Compare: ENTX vs INMB · ENTX vs CNBX · ENTX vs ALT · ENTX vs VIVS · ENTX vs AVTX

Company	Revenue	Growth
VIVS	$135.00K	-3.6%
ENTX	$0	-100.0%
INMB	–	–
CNBX	$0	–
ALT	–	–
AVTX	–	–

Company

Next earnings (est.): Mar 26, 2027, after close
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 20
Held by institutions: 6.2%
Auditor: Kesselman & Kesselman
SEC CIK: 1638097

Advertisement
300 × 250

See a number that looks wrong?